Kirsten Kolatzki-Bornemann - Publications

Real-world utilization patterns and association of dd-cfDNA with biopsy and rejection.

Journal: Frontiers in medicine

Published: May 25, 2026

Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report.

Journal: Frontiers in immunology

Published: April 28, 2026

Improving diagnostic performance of kidney allograft rejection with a model combining relative fraction and absolute copies of donor-derived cell-free DNA-Results from 5 independent cohorts.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: February 04, 2026

A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation.

Journal: Kidney international

Published: January 23, 2026

Association of Blood Donor-derived Cell-free DNA Levels With Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational Study.

Journal: Transplantation direct

Published: January 16, 2025

Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients.

Journal: Acta neuropathologica communications

Published: August 29, 2024

Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 07, 2024